03-12-2018
Artur / iStockphoto.com
AbbVie has granted Pfizer a non-exclusive global licence to its Humira (adalimumab) IP, as announced on Friday, November 30.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Pfizer, adalimumab, licensing agreement, royalties, arthritis, biosimilar, generic competition, marketing authorisation
Allele drops COVID-19 protein suit against Pfizer, BioNTech
06-01-2022
Pfizer drops Xeljanz patent suits
20-04-2021
Clean sweep for AbbVie in Humira litigation
15-05-2019
Abbvie faces multiple Humira antitrust suits
04-04-2019
Pfizer inks licensing deal with Seattle biotech firm
18-12-2018
NHS to save £300m in biosimilar adalimumab deals
29-11-2018
AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
